论文部分内容阅读
目的探讨芳香化酶、雌激素(ER)、孕激素受体(PR)与卵巢浆液性肿瘤的发病机制、临床分期、分化程度的关系以及芳香化酶与ER、PR之间是否具有相关性,进而探讨其临床意义。方法对中国医科大学第一附属医院1995—2002年手术切除的卵巢浆液性乳头状囊腺癌标本36例(恶性组)、卵巢浆液性乳头状囊腺瘤20例(良性组)及非卵巢疾病患者正常卵巢组织标本10例(正常组),用多克隆抗体免疫组化链霉素抗生物素蛋白-过氧化物酶标记法检测其芳香化酶的表达,用免疫组织化学二步法检测ER、PR的表达。结果芳香化酶在恶性组的表达率明显高于正常组及良性组(P<0.05),与恶性组的临床分期和分化程度无关(P>0.05)。ER在恶性组的表达率明显高于正常组及良性组(P<0.05),与恶性组的临床分期和分化程度无关(P>0.05)。PR在正常组及良性组的表达率明显高于恶性组(P<0.05),与恶性组的临床分期和分化程度无关(P>0.05)。结论芳香化酶、ER可能参与卵巢浆液性肿瘤的发生。
Objective To investigate whether the relationship between aromatase, estrogen (ER), progesterone receptor (PR) and ovarian serous tumors is related to the pathogenesis, clinical stage and differentiation degree of aromatase, ER, PR, Then explore its clinical significance. Methods Thirty-six cases of ovarian serous papillary cystadenocarcinoma (malignant group), 20 cases of ovarian serous papillary cystadenoma (benign group) and non-ovarian disease were collected from the First Affiliated Hospital of China Medical University from 1995 to 2002 The normal ovarian tissue specimens of 10 patients (normal group), the polyclonal antibody immunohistochemical streptavidin-peroxidase-labeled method to detect the expression of aromatase, two-step immunohistochemical detection of ER , PR expression. Results The expression of aromatase in malignant group was significantly higher than that in normal group and benign group (P <0.05), but not with the clinical stage and differentiation of malignant group (P> 0.05). The expression of ER in malignant group was significantly higher than that in normal group and benign group (P <0.05), but not in clinical stage and differentiation of malignant group (P> 0.05). The expression of PR in normal group and benign group was significantly higher than that in malignant group (P <0.05), but not in clinical stage and differentiation of malignant group (P> 0.05). Conclusions Aromatase and ER may be involved in ovarian serous tumors.